Seagen Signs an Exclusive WW License Agreement with RemeGen to Develop and Commercialize Disitamab Vedotin
Shots:
- RemeGen to receive $200M up front for development and commercialization rights of disitamab vedotin outside of Remegen’s territory & ~$2.4B upon the achievement of milestones across multiple indications along with royalties on sales of the therapy in Seagen’s territory
- RemeGen will retain development & commercialization rights of the therapy in Asia (Ex-Japan & Singapore). Seagen will be responsible for global development whereas RemeGen will fund and operationalize the portion of clinical trials & lead clinical development and regulatory submissions specific to its territory
- The collaboration leverages companies' expertise in developing ADCs along with Seagen’s development capabilities
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com